Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

Next Previous
Trial Profile

A Phase 2 Trial of neoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan (HER3-DXd; U3-1402) With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Letrozole (Primary) ; Patritumab Deruxtecan (Primary) ; Cyclophosphamide; Doxorubicin; Epirubicin; Paclitaxel
  • Indications Adenocarcinoma; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Acronyms SOLTI VALENTINE; VALENTINE; VALENTINE Trial

Most Recent Events

  • 02 Dec 2024 According to a Daiichi Sankyo Company media release, primary results of this study will be presented as an Oral Presentation on Tuesday, December 10, 6:00 - 7:00 pm at San Antonio Breast Cancer Symposium (#SABCS24).
  • 18 Sep 2023 Status changed from recruiting to active, no longer recruiting.
  • 28 Nov 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top